AZTA at a glance
Azenta, Inc. (AZTA, SEC CIK 933974) filed its latest 10-K annual report on November 19, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 30, 2026 (FY2026), Azenta, Inc. (AZTA) reported revenue of $621.7 million (up 4.7% from FY2025) and a net loss of $167.0 million. Diluted EPS was -$3.70.
- As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Azenta, Inc. (AZTA) shares worth $754.3 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $621.7M
- +4.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 32 funds
- $754.3M · +0 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Sep 30, 2026
Risk Factors
- BIOSECURE Act restrictions, including BGI- or MGI-related platforms, could constrain China-based genomic services and supplier access
- China exposure: $74.4 million revenue and $177.4 million foreign-currency cash in fiscal 2026
- Sole- or limited-source suppliers for cryogenic systems, consumables and genomic services create disruption risk
- AI-enabled discovery and autonomous laboratories could reduce physical testing demand and intensify competition
- CEO resignation on August 22, 2026, leaves a director as Interim CEO during permanent successor search
Business Overview
- Core model: Life sciences sample management and multiomics solutions spanning storage, genomics, consumables, informatics and repository services
- New emphasis: SynPlexity acquisition and Elegen license expanding multiplexed gene libraries and cell-free DNA synthesis
- Strategic shift: B Medical Systems divestiture for $63.0 million, sharpening focus on Sample Management Solutions and Multiomics
- Restructuring: Three North American Multiomics laboratories slated for closure, targeting approximately $11.0 million annualized savings
- Scale: Approximately 2,850 workers, 11,000 customers, sales in approximately 87 countries and 12 genomic laboratories globally
Management Discussion & Analysis
- Revenue $621.7M, up 4.7% YoY from $593.8M, driven by SMS and Multiomics growth
- Gross margin 44.2% vs 45.5%; operating loss $174.7M vs $26.8M, including $149.1M goodwill impairment
- Best segment SMS: revenue $344.4M, adjusted operating income $25.2M; worst Multiomics: adjusted operating loss $15.4M
- Operating cash flow $57.5M; capex $30.1M; share repurchases $118.3M; no dividends planned
- Fiscal 2027 risks: declining Sanger revenue, constrained capital spending, tariffs, lower interest income, and $11.0M to $13.0M restructuring charges
AI summary of the AZTA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- B Medical Systems sold July 1, 2026 for $63.0 million, including $28.0 million cash and $35.0 million vendor financing
- MD&A notes revised June 30, 2025 figures for previously identified financial-statement errors
Risk Factors
- New credit risk triggered by July 1, 2026 B Medical Systems divestiture and $35.0 million secured buyer loan
- Buyer repayment risk: $35.0 million principal plus 6.0% interest due three months after funding
- Related-party enforcement risk from buyer majority ownership by an Azenta officer
- Collateral recovery risk limited to pledged B Medical Systems equity
AI summary of the AZTA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal fourth-quarter and full-year 2026 results announced for period ended September 30, 2026
- Detailed financial results and management commentary contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- FY26 revenue $622M, up 5% reported and 2% organically, but adjusted EBITDA fell 12% to $58.3M
- FY26 GAAP operating loss $174.7M, including $149.1M goodwill and intangible impairment
Item 1.01: Entry into a Material Definitive Agreement
- Exclusive, royalty-free Elegen gene-synthesis license expands GENEWIZ manufacturing and global service capabilities
- Initial license term five years, with conversion option to perpetual exclusive rights for $25 million
Item 8.01: Other Events
- Azenta acquired all SynPlexity shares on October 28, 2026, expanding its DNA assembly capabilities
- SynPlexity technology targets large, multiplexed gene libraries for screening, drug discovery and therapeutics
Item EX-99.1: Item EX-99.1
- Exclusive Elegen license adds cell-free DNA synthesis, targeting higher quality, faster delivery, and scalable regional production
- SynPlexity acquisition adds pooled assembly libraries with thousands of full-length gene variants for high-throughput discovery
Item 7.01: Regulation FD Disclosure
- October 30, 2026 press release announces Azenta’s acquisition of SynPlexity
- Release also highlights contractual arrangements with Elegen
Item 2.06: Material Impairments
- Estimated $9.0 million impairment charge tied primarily to lease right-of-use assets and leasehold improvements
- Charges reflect planned facility exits before lease expirations, signaling footprint reduction under the restructuring plan
Item 2.05: Costs Associated with Exit or Disposal Activities
- Multiomics restructuring: three North American laboratory closures and workforce reductions
- Pre-tax charges estimated at $11.0M-$13.0M, including approximately $9.0M impairments and $3.0M severance
AI summaries of AZTA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AZTA
Don't miss the next AZTA filing
- Alerts as it files. A push when AZTA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AZTA, by share count.
- Ask anything. An AI agent that reads every AZTA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Lin Lawrence Y. | F | Nov 16, 2026 | 4,413 | $43.86 |
| Pirogova Olga | A | Nov 16, 2026 | 13,412 | - |
| Pirogova Olga | F | Nov 16, 2026 | 2,072 | $43.86 |
| Pirogova Olga | F | Nov 16, 2026 | 5,009 | $43.86 |
| Pirogova Olga | A | Nov 12, 2026 | 10,339 | - |
| Bello Erik J. | A | Nov 12, 2026 | 5,815 | - |
| MARTIN WILLIAM E. III | A | Nov 12, 2026 | 17,576 | - |
| Starr Ephraim | A | Nov 12, 2026 | 21,711 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $593.8M | $621.7M |
| Gross Profit | - | $270.3M | $275.0M |
| Operating Income | - | -$26.8M | -$174.7M |
| Net Income | - | -$55.8M | -$167.0M |
| Gross Margin | - | 45.5% | 44.2% |
| Op. Margin | - | -4.5% | -28.1% |
| Net Margin | - | -9.4% | -26.9% |
| Balance Sheet | |||
| Total Assets | $2.0B | $2.1B | $1.7B |
| Equity | - | $1.7B | $1.4B |
| ROE | - | -3.2% | -12.0% |
| Per Share | |||
| EPS | - | $-1.22 | $-3.70 |
| Cash Flow | |||
| Operating CF | - | $72.2M | $57.5M |
| CapEx | $37.4M | $33.9M | $30.1M |
Source: XBRL data in Azenta, Inc. (AZTA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate AZTA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 32 | $754.3M |
| Q2 2026 | 32 | $572.5M |
| Q1 2026 | 30 | $427.9M |
| Q4 2025 | 29 | $737.1M |
| Q3 2025 | 30 | $652.9M |
| Q2 2025 | 30 | $728.8M |
| Q1 2025 | 27 | $512.0M |
| Q4 2024 | 24 | $601.5M |
- Millennium Management+215.1K (+132%)
- JPMorgan Chase & Co+135.4K (+56%)
- Franklin Resources+129.7K (+1040%)
- Goldman Sachs Group+108.2K (+28%)
- Ameriprise Financial+16.3K (+2%)
- BlackRock−511.7K (-7%)
- D.E. Shaw & Co−209.8K (-16%)
- Bank of America Corp−192.7K (-29%)
- Morgan Stanley−184.7K (-14%)
- Raymond James Financial−140.7K (-80%)
- Renaissance Technologies LLC+288.7K
- FMR LLC (Fidelity)−5.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 234 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AZTA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-K | Nov 19, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 8-K | Oct 30, 2026 | - | Analysis | - |
| 4 | Oct 23, 2026 | - | - | - |
| 8-K | Oct 7, 2026 | - | Analysis | - |
| 4 | Sep 23, 2026 | - | - | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 8-K | Sep 4, 2026 | - | Analysis | - |
| 8-K | Aug 24, 2026 | - | Analysis | - |
| 4 | Aug 11, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- ACHC · Acadia Healthcare Company IncServices-Specialty Outpatient Facilities, NEC
AZTA SEC filings: frequently asked questions
Which institutions hold AZTA stock?
As of September 30, 2026, the largest Azenta, Inc. (AZTA) holders among the 13F filers tracked by SignalX were BlackRock ($244.8 million), Vanguard Portfolio Management LLC ($84.9 million), State Street Corp ($62.2 million), Vanguard Capital Management LLC ($60.8 million), Dimensional Fund Advisors ($41.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AZTA's revenue in fiscal year 2026?
For the fiscal year ended September 30, 2026 (FY2026), Azenta, Inc. (AZTA) reported revenue of $621.7 million (up 4.7% from FY2025) and a net loss of $167.0 million. Diluted EPS was -$3.70. The figures come from the XBRL data in the 10-K.
What are the main risks in AZTA's latest 10-K?
In the 10-K filed November 19, 2026, Azenta, Inc. (AZTA) flagged: BIOSECURE Act restrictions, including BGI- or MGI-related platforms, could constrain China-based genomic services and supplier access. China exposure: $74.4 million revenue and $177.4 million foreign-currency cash in fiscal 2026. (AI summary of the Risk Factors section.)
What did AZTA report in its latest 8-K?
Azenta, Inc. (AZTA) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal fourth-quarter and full-year 2026 results announced for period ended September 30, 2026.
What are the latest AZTA SEC filings?
Azenta, Inc. (AZTA) filed its latest 10-K annual report on November 19, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 16, 2026.
What is AZTA's SEC CIK number?
Azenta, Inc. (AZTA)'s SEC Central Index Key (CIK) is 933974. EDGAR lists every AZTA filing under that number.
Ask anything about AZTA
The research agent reads AZTA's filings, financials, insider trades and 13F holders, then answers with sources.